The best trial we have says cannabis made Crohn's patients feel meaningfully better and did nothing measurable to their inflammation. Both halves of that sentence matter, and most places you will read about this only quote the first one.
What patients are managing
Crohn's disease and ulcerative colitis are qualifying conditions in Pennsylvania, and patients typically arrive already on disease-modifying therapy, looking for help with what the medication does not reach: pain, urgency, appetite, nausea, sleep, and the exhaustion of managing all of it. That is a legitimate goal, and it is a different goal from treating the disease.
What the research supports: cannabinoids
A double-blind, randomized, placebo-controlled, single-center trial followed 56 Crohn's patients for eight weeks on a CBD-rich oil that also contained THC. Clinical disease activity improved. Quality of life improved. Endoscopic scores did not, and neither did inflammatory markers including CRP and calprotectin. The authors concluded that cannabis improved symptoms but did not demonstrate reduced gut inflammation, and should be used only within clinical trials. Across the small trials done to date that pattern holds, and no IBD cannabinoid trial has clearly met an inflammatory or endoscopic primary endpoint.
What the research supports: terpenes
Beta-caryophyllene is the only terpene with a real rationale here, and the mechanism is unusually well demonstrated for a preclinical finding. In mice with chemically induced colitis, oral beta-caryophyllene reduced disease activity, colon damage and pro-inflammatory cytokines, and the effect disappeared when researchers blocked either the CB2 receptor or the PPAR-gamma pathway, which tells you the pathway is genuine and not a coincidence. Those were mice, given isolated beta-caryophyllene from clove and spice sources, not patients using a cannabis terpene profile.
What the research does not support
There is no human terpene evidence for Crohn's or IBD at all. The symptomatic benefit in the trials appears to depend on THC, a cannabinoid Terpenology does not score, and even that did not touch inflammation. Nothing on this page is a substitute for the drugs that actually modify the disease, and nobody has shown that any cannabis product protects your gut. A high Fit score for Crohn's would not be defensible, so Terpenology will not show you one.
How Terpenology scores this
Terpenology caps the Crohn's Fit score at low confidence by design, and frames it as targeting comfort rather than disease control. A beta-caryophyllene-forward panel can earn a modest score with the preclinical caveat attached to it. It cannot earn a high one. If that feels like the app underselling itself, it is: we would rather be the tool you can still trust in two years.
Terpenes worth reading about
Terpenology is educational, not medical advice. Terpene effects are tendencies commonly reported by patients and early research, never guaranteed outcomes. Nothing here is a substitute for the care of your certifying physician, your pharmacist, or the specialist treating your condition.